Pharmaceuticals, Biotechnology and Life Sciences
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
ThromboGenics will pay preclinical milestone to Bicycle Therapeutics in connection with the advancement of a Bicycle (bicyclic peptide) into preclinical development for the treatment of diabetic macular edema.
Diplomat Pharmacy will distribute Zejula (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Redx Pharma has a new Chairman of the Board of Directors and a Non-Executive Director of the company.
Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, has appointed Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance.
Forward Pharma has reported financial results for the year ended December 31, 2016.